Article

AJMC® in the Press, March 3, 2017

Author(s):

Coverage of our peer-reviewed research in the healthcare and mainstream press.

The National Pharmaceutical Council’s daily newsletter on Monday highlighted a video interview posted by The American Journal of Managed Care® (AJMC®). The interview with Jonathan Hirsch, founder and president of Syapse, focused on the use of precision medicine in value-based oncology. “We really think that precision medicine is the future of cancer care, and we look forward to democratizing access for many health systems,” said Hirsch.

An article published this week in the Journal of Health Care for the Poor and Underserved about specialty care access within the safety net cited an AJMC® study, “Increasing Access to Specialty Care: Patient Discharges From a Gastroenterology Clinic.” In that study, researchers from San Francisco General Hospital found that discharging patients from specialty care to primary care for follow-up effectively improved access to specialty care for safety net patients.

This week, Rheumatology International published a review of the function of myeloid dendritic cells in rheumatoid arthritis (RA). The review referenced an article that was published by AJMC® in a supplement about RA. The article, titled “Overview of Epidemiology, Pathophysiology, and Diagnosis of Rheumatoid Arthritis,” was written by Allan Gibofsky, MD, who recently took part in a series of AJMC® video interviews, including one where he discussed the need for individualized treatments in RA.

Related Videos
Fulling and Cournoyer
Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network
Tiara Green, MSEd
Panagis Galiatsatos, MD, MHS, an expert on bronchiectasis
Panagis Galiatsatos, MD, MHS, an expert on bronchiectasis
Jason Porter, MD, an expert on lung cancer
Jason Porter, MD, an expert on lung cancer
Joseph Mikhael, MD, an expert on multiple myeloma
A panel of 3 experts on multiple sclerosis
A panel of 3 experts on multiple sclerosis
Related Content
CH LogoCenter for Biosimilars Logo